A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.

Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, Stathis A, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz NA, Kurtovic S, Schorb E, Schmidt C, Dimitrijević S, Dreyling M

Open source

DOI: 10.1097/hs9.0000000000000656
Published: 2021 Nov
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hs9.0000000000000656,
  title = {A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.},
  author = {Collins GP and Eyre TA and Schmitz-Rohmer D and Townsend W and Popat R and Giulino-Roth L and Fields PA and Krasniqi F and Soussain C and Stathis A and Andjelkovic N and Cunningham D and Mandic D and Radulovic S and Tijanic I and Horowitz NA and Kurtovic S and Schorb E and Schmidt C and Dimitrijević S and Dreyling M},
  year = {2021},
  journal = {HemaSphere},
  doi = {10.1097/hs9.0000000000000656},
  url = {https://doi.org/10.1097/hs9.0000000000000656}
}

RIS

TY  - JOUR
TI  - A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
AU  - Collins GP
AU  - Eyre TA
AU  - Schmitz-Rohmer D
AU  - Townsend W
AU  - Popat R
AU  - Giulino-Roth L
AU  - Fields PA
AU  - Krasniqi F
AU  - Soussain C
AU  - Stathis A
AU  - Andjelkovic N
AU  - Cunningham D
AU  - Mandic D
AU  - Radulovic S
AU  - Tijanic I
AU  - Horowitz NA
AU  - Kurtovic S
AU  - Schorb E
AU  - Schmidt C
AU  - Dimitrijević S
AU  - Dreyling M
PY  - 2021
JO  - HemaSphere
DO  - 10.1097/hs9.0000000000000656
UR  - https://doi.org/10.1097/hs9.0000000000000656
ER  -

APA

GP, C., TA, E., D, S., W, T., R, P., L, G., PA, F., F, K., C, S., A, S., N, A., D, C., D, M., S, R., I, T., NA, H., S, K., E, S., C, S., S, D., & M, D. (2021). A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.. HemaSphere. https://doi.org/10.1097/hs9.0000000000000656

Source records

pubmed · retrieved 2026-09-26T23:16:02.818Z